New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Passage Bio, Inc.

PASG

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

3.92 0.31 +8.59%
Market cap
$11.6M
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
0.00%
Net debt / EBITDA
1.0×
Payout ratio
—

Ratios over time FY19 to FY25

Returns on capital

ROIC was 0.00% in FY25, the highest of these seven years.

ROEROIC
FY19FY20FY21FY22FY23FY24FY25
ROE133.4%−90.3%−59.5%−52.4%−65.3%−75.1%−113.8%
ROIC0.0%0.0%−4025.0%−735.8%0.0%0.0%0.0%

Debt

Net debt is 0.96× a year’s EBITDA. Debt is 0.00× equity.

Debt / equityNet debt / EBITDA
FY18FY19FY20FY21FY22FY23FY24FY25
Debt / equity0.0×0.0×0.0×0.0×0.0×0.0×0.0×0.0×
Net debt / EBITDA2.5×4.3×2.7×1.7×1.4×1.1×1.1×1.0×
Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Current Ratio
— 108.79 45.04 14.98 11.02 10.74 7.22 4.07 2.07
Net Debt/EBITDA
— 2.46 4.29 2.73 1.74 1.42 1.07 1.11 0.96
Debt/Equity
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE
— 37.32% 133.38% (90.34%) (59.48%) (52.35%) (65.29%) (75.07%) (113.78%)
ROA
— (76.33%) (43.04%) (44.31%) (54.28%) (45.48%) (51.80%) (51.21%) (55.28%)
ROIC
— — 0.00% 0.00% (4,024.99%) (735.76%) 0.00% 0.00% 0.00%
Return on Tangible Assets
— (38.56%) (27.97%) (37.56%) (58.05%) (67.65%) (87.30%) (94.16%) (158.14%)
Free Cash Flow per Share
— (0.41) (196.36) (42.56) (57.18) (45.37) (28.65) (15.59) (9.56)
Book value per Share
— (0.27) (265.59) 157.82 119.47 73.99 40.66 19.90 5.91
Free Cash Flow
— (18.57) (41.59) (82.17) (152.52) (123.48) (78.41) (47.99) (30.34)
Other line items

Show all line items

Columns are period end dates · fundamentals updated Nov 12, 2026